Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT13387Xx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparibXx_NEWLINE_xX